SNDX - Syndax Pharmaceuticals Inc logo

SNDX

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals develops therapies for cancer, including Revuforj for acute leukemia and Niktimvo for chronic graft-versus-host disease. Its pipeline includes treatments for acute myeloid leukemia, metastatic colorectal cancer, and idiopathic pulmonary fibrosis.

โš•๏ธ Healthcare NASDAQ Listed 2016 $ USD
$1,000 invested 10 years ago โ†’$1,413today

Score Overview

1 Year
Score
Net Growth22.65%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth46.21%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.4
Net Growth-8x
Net Trend40%
Net Income Consistencyโ€”
Rev Growth80.38%
Rev Trend60%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-396.41%
Net Trend40%
Net Income Consistency
Rev Growth206x
Rev Trend50%
Revenue Consistency
All Time
Score
Net Growth-396.41%
Net Trend40%
Net Income Consistency
Rev Growth206x
Rev Trend50%
Revenue Consistency

See the full market ranking โ†’

Syndax Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 1M to $ 172M and net income went from -$ 73M to -$ 285M. Revenue increased in 3 of those 5 years; net income in 2.

Across Syndax Pharmaceuticals Inc's full reported history, from 2016 to 2025, revenue grew from $ 1M to $ 172M and net income went from -$ 44M to -$ 285M. Revenue increased in 50% of the years measured; net income in 40%.

Syndax Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 19.80โ€”
1 Year2025-08-12
$ 12.9752.66%
5 Years2021-08-12
$ 15.6726.36%
10 Years2016-08-12
$ 14.0141.33%
All Time2016-03-03
$ 12.0164.86%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 252M-$ 220M$ 547M
2025$ 172M-$ 285M$ 413M
2024$ 23M-$ 318M$ 582M
2023$ 0.00-$ 209M$ 577M
2022$ 126M-$ 143M$ 484M
2021$ 139M$ 24M$ 446M
2020$ 1M-$ 73M$ 293M
2019$ 1M-$ 55M$ 59M
2018$ 1M-$ 73M$ 80M
2017$ 2M-$ 60M$ 133M
IPO2016$ 1M-$ 44M$ 105M

Explore beyond SNDX

You're looking at Syndax Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies